180 related articles for article (PubMed ID: 17136110)
1. A new era in phosphate binder therapy: what are the options?
Salusky IB
Kidney Int Suppl; 2006 Dec; (105):S10-5. PubMed ID: 17136110
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for hyperphosphatemia.
Bellinghieri G; Santoro D; Savica V
Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
[TBL] [Abstract][Full Text] [Related]
3. Lanthanum carbonate as a first-line phosphate binder: the "cons".
Drüeke TB
Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic effects of the non-calcium phosphate binder sevelamer.
Nikolov IG; Joki N; Maizel J; Lacour B; Drüeke TB; Massy ZA
Kidney Int Suppl; 2006 Dec; (105):S16-23. PubMed ID: 17136111
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
6. Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
Cozzolino M; Brancaccio D
Expert Opin Emerg Drugs; 2007 Sep; 12(3):341-3. PubMed ID: 17874964
[TBL] [Abstract][Full Text] [Related]
7. The phosphate binder equivalent dose.
Daugirdas JT; Finn WF; Emmett M; Chertow GM;
Semin Dial; 2011; 24(1):41-9. PubMed ID: 21338393
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
11. Hyperphosphatemia and phosphate binders.
Schucker JJ; Ward KE
Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
[TBL] [Abstract][Full Text] [Related]
12. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
Frazão JM; Adragão T
Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
[TBL] [Abstract][Full Text] [Related]
13. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
14. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Noto L
J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
[TBL] [Abstract][Full Text] [Related]
15. [Management of hyperphosphatemia ; phosphate-binder].
Yokoyama K
Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
[TBL] [Abstract][Full Text] [Related]
16. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
17. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
18. Lanthanum carbonate--a first line phosphate binder?
de Freitas D; Donne RL; Hutchison AJ
Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
[TBL] [Abstract][Full Text] [Related]
19. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
Lorenzo Sellares V; Torres Ramírez A
Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
[TBL] [Abstract][Full Text] [Related]
20. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
